Impax Laboratories division Impax Pharmaceuticals has resubmitted its new drug application (NDA) for Rytary (IPX066) to the US Food and Drug Administration (FDA) for treatment of patients with Parkinson’s disease (PD).

PD is a chronic neurodegenerative movement disorder that affects more than three million people in the US, Europe and Japan.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

IPX066 is a patented extended-release capsule formulation of carbidopa and levodopa, an investigational drug, indicated to treat idiopathic PD.

"FDA will inspect the manufacturing facilities involved in the production of Rytary in connection with the resubmission."

The company has provided updated safety and stability information in the resubmitted NDA for Rytary.

According to the company, FDA will inspect the manufacturing facilities involved in the production of Rytary in connection with the resubmission.

In addition, the FDA has designated the NDA filing of Rytary as a Class 2 resubmission for review purposes and has 14 days to officially accept the resubmission.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Results from the Phase III trials of IPX066, APEX-PD (early PD), ADVANCE-PD (advanced PD) and ASCEND-PD (advanced PD) were useful for the NDA resubmission.

Rytary is currently not approved or licensed anywhere in the world.

Impax Laboratories is applying its formulation expertise and drug delivery technology in the development of controlled-release and specialty generics in addition to the development of central nervous system disorder branded products.